Pharma & Biotech Global Week in Review 14 March 2012 from IP Think Tank
Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Highlights this week included:
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
Neglected tropical disease (infectious diseases) drugs: What are they telling us about innovations! (profitability through simplicity)
Genetic heterogeneity in tumor samples may explain difficulties in developing personalized medicine (Patent Docs)
Europe moving away from pay-for-delay? (IP Whiteboard)
Kenya waits on landmark decision affecting access to drugs due out today (Afro-IP)
Mexico defines orphan drugs, but leaves questions unanswered (IP tango)
US: FDA cements “it’s our party and we’ll punt if we want to” stance on 180-day exclusivity failure to obtain tentative approval forfeiture decisions (FDA Law Blog)
US: Lawsuits allege that coupons and savings programs for brand-name drugs violate RICO, antitrust law (FDA Law Blog)
US: Safe harbor does not apply to products not requiring regulatory approval: PSN Illinois v Abbott Labs (Chicago IP Litigation Blog)
US: Attacks on Medtronic & OrbusNeich medical device patents among the reexamination requests filed the week of March 5, 2012 (WHDA)
Megace ES (Megestrol Acetate) – US: FDA’s brief in Par: the gift that keeps on giving (FDA Law Blog)
Oxycodone – EU: An unfinished battle and an undisclosed question – infringement proceedings in UK, Netherlands, Germany, Norway and Finland and EPO opposition re EP 722 730 (Kluwer Patent Blog)
Seroquel (Quetiapine) – Netherlands: District Court of The Hague denies requested invalidation of sustained release quetiapine patent: Sandoz v AstraZeneca (EPLAW)